The most common side effects include conjunctival (eye) redness, eye irritation, and eye discomfort (pain).[4] Latanoprostene bunod may cause the iris (colored part of the eye) to become darker in color.[4]
Latanoprostene bunod was approved for medical use in the United States in November 2017.[2][4][5]
Medical uses
Latanoprostene bunod is indicated for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2]
History
The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension.[4] The trials evaluated the benefits and side effects of latanoprostene bunod.[4] In each trial, participants were randomly assigned to receive either latanoprostene bunod or an approved drug timolol (ophthalmic solution) every day for three months.[4] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed.[4] The trials were conducted in the United States, the United Kingdom, Germany, Italy, Bulgaria, the Czech Republic, and Japan.[4]